Tainkang: The controlling subsidiary CKBA Cream Rosacea Indication Phase IIa clinical trial has completed enrollment of all subjects.

Tainkang announces that its subsidiary, Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., has completed enrollment of all subjects in the Phase IIa clinical trial of the Class 1 innovative drug CKBA Cream for rosacea indications, and has obtained preliminary positive and effective trial data. The company plans to initiate Phase IIb clinical trials ahead of schedule.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned